Advertisement

Topics

Latest "Boehringer Ingelheim Corporation" News Stories - Page: 3

11:11 EDT 24th March 2019 | BioPortfolio

Here are the most relevant search results for "Boehringer Ingelheim Corporation" found in our extensive news archives from over 250 global news sources.

More Information about Boehringer Ingelheim Corporation on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Boehringer Ingelheim Corporation for you to read. Along with our medical data and news we also list Boehringer Ingelheim Corporation Clinical Trials, which are updated daily. BioPortfolio also has a large database of Boehringer Ingelheim Corporation Companies for you to search.

Showing "Boehringer Ingelheim Corporation" News Articles 51–75 of 986

Extremely Relevant

Boehringer Ingelheim buys Austrian firm ViraTherapeutics for €210m

ViraTherapeutics is engaged in the development of virus-based immunotherapeutics for the treatment of cancer. The current deal is based on an option and share purchase agreement signed by The post Boehringer Ingelheim buys Austrian firm ViraTherapeutics for €210m appeared first on Pharma Business review.


Boehringer buys ViraTherapeutics

Boehringer Ingelheim has exercised an option to acquire all shares of oncolytic virus company ViraTherapeutics.

Boehringer buys ViraTherapeutics to help make ‘cold’ tumours ‘hot’

Boehringer Ingelheim will pay â210m for ViraTherapeutics to boost viral-based immune-oncology R&D.


Boehringer Ingelheim and Sandoz abandon biosimilars

Boehringer Ingelheim has decided to abandon biosimilars outside the US. While Sandoz has decided not to pursue biosimilar rituximab in the US.

Boehringer enters CNS drug discovery deal with Domain

Boehringer Ingelheim and Domain Therapeutics agreed to work together to research and develop an undisclosed number of therape -More- 

Boehringer Ingelheim Expands Shanghai Biologics CDMO Facility

Boehringer Ingelheim has begun an expansion of Oasis, its Shanghai biologic contract manufacturing facility, including an additional bioreactor and sufficient infrastructure to support the GMP operations of 2x2000L single use bioreactor manufacturing lines. BI explained that one of its contracted mAbs is close to commercial production, with several additional candidates in its pipeline expected to...

Boehringer Ingelheim and $EPZM Worldwide Collab to Develop Novel Epigenetic Oncology Therapies. Epizyme will receive $15M & eligible to milestone payments https://www.businesswire.com/news/home/20181115005422/en/Boehringer-Ingelheim-Epizyme-Announce-World

Boehringer Ingelheim and $EPZM Worldwide Collab to Develop Novel Epigenetic Oncology Therapies. Epizyme will receive $15M & eligible to milestone payments https://www.businesswire.com/news/home/20181115005422/en/Boehringer-Ingelheim-Epizyme-Announce-Worldwide-Collaboration-Develop …

GSK Nabs Boehringer Ingelheim's Chief Medical Officer Christopher Corsico

Germany-based Boehringer Ingelheim announced earlier this week that Christopher Corsico, senior vice president, Corporate Division Medicine and chief medical officer, was leaving the company effective December 31. Today it was announced that Corsico will join UK-based GlaxoSmithKline to take on t...

M&As this week: Cambrex Corporation, Boehringer Ingelheim, Supernus Pharmaceuticals

Cambrex Corporation has completed the previously announced acquisition of Halo Pharma (Halo) for $425m. Cambrex is a life sciences company...Read More... The post M&As this week: Cambrex Corporation, Boehringer Ingelheim, Supernus Pharmaceuticals appeared first on Pharmaceutical Technology.

Boehringer Expands Biopharmaceuticals in US

Germany’s Boehringer Ingelheim has opened a new US biopharmaceutical manufacturing facility at Fremont, California, expanding its worldwide bioreactor capacity to 290,000 liters. The US plant, which cost €200 million to build, employs 300 people.

Boehringer Ingelheim GmbH Mergers Acquisitions MA, Partnerships Alliances and Investment Report [Report Updated: 28072018] Prices from USD $350

Boehringer Ingelheim GmbH Mergers Acquisitions MA, Partnerships Alliances and Investment ReportSummaryMarketline's Boehringer Ingelheim GmbH Mergers Acquisitions MA, Partnerships Alliances and Investments report includes business description, detailed reports on mergers and acquisitions MA, divestments, capital raisings, venture capital investments, ownership and partnership transactions unde...

EMBL Ventures Portfolio Company, ViraTherapeutics Acquired by Boehringer Ingelheim in EUR 210 Million Transaction

EMBL Ventures announced that Boehringer Ingelheim has exercised its option to acquire EMBL Ventures' portfolio company ViraTherapeutics in a transaction with a total value of EUR 210 million (USD 245 million). The acquisition follows a collaboration and option agreement signed between ViraTherapeuti...

Boehringer partners with Epizyme to develop new cancer therapies

Boehringer Ingelheim has formed a global alliance with US-based biopharmaceutical firm Epizyme for the research, development and commercialisation of new...Read More... The post Boehringer partners with Epizyme to develop new cancer therapies appeared first on Pharmaceutical Technology.

University and Boehringer Ingelheim provide free access to PROTAC compound on opnMe.com

(University of Dundee) A PROTAC COMPOUND developed at the University of Dundee is being made available free of charge by the pharmaceutical company Boehringer Ingelheim through their scientific crowdsourcing platform opnMe.com. The opnMe portal provides free and open access to selected molecules for the scientific community aiming at accelerating research initiatives that can benefit patients with...

Boehringer follows Sanofi with job cuts in France

Boehringer Ingelheim has confirmed it plans to axe more than 10% of its workforce in France, or more than 300 jobs, adding to several hundred losses at Sanofi last week. The privately-held German drugmaker says it will eliminate 327 positions – 19...

Boehringer and Bioharmony partner to develop therapies for bacterial infections

Bioharmony Therapeutics Inc. and Boehringer Ingelheim GMBH agreed to collaborate on the development of bacteriophage lysins f...

Boehringer exercises option to buy ViraTherapeutics for $245m

Boehringer Ingelheim has acquired all of the shares in biopharmaceutical firm ViraTherapeutics for €210m ($245m) based on an option and...Read More... The post Boehringer exercises option to buy ViraTherapeutics for $245m appeared first on Pharmaceutical Technology.

GSK grabs new drug development head from Boehringer

GlaxoSmithKline has hired Chris Corsico from German drugmaker Boehringer Ingelheim to fill the new role of senior vice-president development as the company reshapes its research strategy, a spokesman for the British group said on Tuesday.

Boehringer continues to threaten AbbVie’s US patents for Humira

Boehringer Ingelheim (BI) has not given up on the US patent dispute with AbbVie on Humira (adalimumab). Recently, the company...Read More... The post Boehringer continues to threaten AbbVie’s US patents for Humira appeared first on Pharmaceutical Technology.

Relevant

Boehringer closes enrolment in Phase IIa trial for NASH

Boehringer Ingelheim has completed enrolment of patients in a Phase IIa clinical trial for the assessment of BI 1467335 to...Read More... The post Boehringer closes enrolment in Phase IIa trial for NASH appeared first on Drug Development Technology.

Boehringer and Lilly's Jardiance Looks Good for Type I Diabetes

Boehringer Ingelheim and Eli Lilly released data from their Empagliflozin as Adjunctive to inSulin thErapy (EASE) Phase III trial in type 1 diabetes.

Boehringer files for new rare disease use for nintedanib in EU, US

Boehringer Ingelheim has filed for a new use for its lung drug nintedanib in the US and Europe, bidding to add the rare disease systemic sclerosis to the existing indication for idiopathic pulmonary fibrosis (IPF). The German pharma said it had fi...

Boehringer Ingelheim announces FDA and EMA regulatory submission for nintedanib in systemic sclerosis associated ILD

Systemic sclerosis (SSc), also known as scleroderma, is a rare chronic connective tissue disease Pulmonary fibrosis, or fibrosing interstitial lung disease (ILD), is a key driver of mortality in people living with SSc and constitutes a high unmet need1,2 Improving the lives of people living with pulmonary fibros...

Boehringer employees visit cancer patient homes during holidays

Boehringer Ingelheim and the Bonnie J. Addario Lung Cancer Foundation have come together through the "Bring Hope Home for the Holidays" partnership, aimed at helping lung cancer patients.

Boehringer Ingelheim’s Humira biosimilar meets endpoint


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks